Peg-interferon plus ribavirin in chronic hepatitis C: cost-efficacy and pharmacoutilization in clinical practice
The current standard of care for the treatment of chronic hepatitis C virus (HCV) infection is combination therapy with Peg-interferon (IFN) alpha-2a or alpha-2b type plus ribavirin (RBV). This antiviral schedule can in fact avoid the three fold mortality rates associated to untreated cases with HCV...
Main Authors: | Luisa Cavalletto, Elisabetta Bernardinello, Giulio Diodati, Enzo Raise, Angelo Gatta, Liliana Chemello |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd Medical Publishers
2008-01-01
|
Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
Subjects: | |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/235 |
Similar Items
-
PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE (SVR) TO PEGYLATED INTERFERON ALPHA (PEG-IFN α) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C INFECTED WITH GENOTYPE 1.
by: Krasimir Antonov, et al.
Published: (2011-12-01) -
Changes in miR-122 and Cholesterol Expression in Chronic Hepatitis C Patients after PegIFN-Alpha/Ribavirin Treatment
by: Malgorzata Sidorkiewicz, et al.
Published: (2020-06-01) -
Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon – Ribavirin in daily practice
by: Ezequiel Ridruejo, MD., et al.
Published: (2010-01-01) -
Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts
by: Lin Kung-Hung, et al.
Published: (2012-01-01) -
Hematological Side Effects During Combination Therapy With Interferon and Ribavirin In Chronic Hepatitis C
by: Komal Owais
Published: (2015-06-01)